| |
|
|
| | AGID O,LERER B.Algorithm-based treatment of major depression
in an outpatient clinic: clinical correlates of response to a specific
serotonin reuptake inhibitor and to triiodotyronine augmentation. Int
J Neuropsychopharmacol 2003; 6: 41-49
AGÜERA-ORTIZ LF, GONZÁLEZ PARRA S, SÁNCHEZ PIEDRA R, PALOMO T.
Patrones de uso de los antiguos y nuevos antidepresivos en pacientes
geriátricos con depresión. Actas Españolas Psiquiátricas 2000; 28:343-352
ALPERT JE, MISCHOULOND D, RUBENSTEIN GE, BOTTONARI K, NIERENBERG AA,
FAVA M. Folinic acid (leucovorin) as an adjunctive treatment for
SSRI-refractory depression. Ann Clin Psychiatry 2002; 14:33-38
ALPERT JE. SAMe, folate, and B12: one-carbon metabolism and depression.
Program and Abstracts of the APA 2004 Annual Meeting, Symposium
196, 1-6-2004. New York, NY.
ÁLVAREZ E, UDINA C, CASAS M, GUILLAMAT R. Tratamiento de las depresiones
refractarias [Treating refractory depressions]. Acta de la 11
Reunión Nacional de Psiquiatría Biológica, Gijón, Arcano, 1985, 265-270
ÁLVAREZ E, PÉREZ-SOLA V, PÉREZ-BLANCO J, QUERALTO JM, TORRUBIA R, NOGUERA R.
Predicting outcome of lithium added to antidepressants in
resistant depression. J Affect Dis 1997; 42:179-186
ÁLVAREZ E, PÉREZ V, PASCUAL JC. Protocolo de tratamiento de trastornos
afectivos refractarios en el HSCSP. Protocolos Hospital de San Pablo
de Barcelona. Barcelona, 1999
ÁLVAREZ E, PÉREZ-SOLÁ V, PÉREZ-BLANCO J. Tratamiento de la depresión
resistente. En Roca M, coordinador. Trastornos del humor. Barcelona:
Ed Panamericana, 1999
BAKISH D. Potentation of fluoxetine by buspirone and trazodone in
refractory depression. In: NOLEN WA, ZOHAR J, ROOSE SP, AMSTERDAM JD,
eds. Refractory depression: current strategies and future directions.
John Wiley&Sons, Chichester, 1994
BAKISH ET AL, BAKISH D, HOOPER CL, WEST DL ET AL. Moclobemide ans
specific serotonin reuptake inhibitor combination treatment of
resistant anxiety and depressive disorders. Human Psychopharmacol
1995; 10:105-109.
BARBEE JG, JAMHOUR NJ. Lamotrigine as an augmentation agent in
TREATMENT-RESISTANT DEPRESSION. J CLIN PSYCHIATRY 2002; 63:737-741
BARBOSA L, BERK M, VORSTER M. A double-blind, randomized,
placebo-controlled trial of augmentation with lamotrigine or
placebo in patients concomitantly treated with fluoxetine for
resistant major depressive episodes. J Clin Psychiatry 2003; 64:403-407
BARON BM, OGDEN AM, SIEGEL BW, STEGEMAN J, URSILLO RC, DUDLEY MW.
Rapid down regulation of beta-adrenoceptors by co-administration of
desipramineand fluoxetine.Eur J Pharmacol. 1988 Sep 13;154(2):125-34.
BAUER M, DOPFMER S. Lithium augmentation in treatment-resistant
depression: meta-analysis of placebo-controlled studies. J Clin
Psychopharmacol 1999; 19:427-434. Erratum: J Clin Psychopharmacol 2000; 20:287
BAUER M, FORSTHOFF A, BAETHGE C, ADLI M, BERGHOFER A, DOPFMER S, BSCHOR T.
Lithium augmentation therapy in refractory depression-update
2002. Eur Arch Psychiatry Clin Neurosci 2003; 253:132-139
BAUMANN P, SOUCHE A, MONTALDI S, et al. A double-blind, placebo-controlled
study of citalopram with and without lithium in the treatment of therapy-resistant
depressive patients: a clinical, pharmacokinetic and pharmacogenetic investigation.
J Clin Psychopharmacol 1996;
16:307-314
BENAZZI F. Serotonin syndrome with mirtazapine-fluoxetine combination.
Int J Geriat Psychiatry 1998; 13:493-496
BERLANGA C, ORTEGA-SOTO HA, ONTIVEROS M, SENTIES H. Efficacy of S-adenosyl
L-methionine in speeding the onset of action of imipramine.
Psychiatry Res 1992; 44:257-262
BERLANGA C, ORTEGA-SOTO HA. A 3-year follow-up of a group of treatment-resistant
depressed patients with aMAOI/tricyclic combination.J
Affect Disord. 1995 Jun 8;34(3):187-92.
BESSON A, HADDJERI N, BLIER P, DE MONTIGNY C. Effects of the co-administration
of mirtazapine and paroxetine on serotonergic
neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000; 10:177-188
BHATARA VS, MAGNUS R, LYNN P, PRESKORN S. Serotonin syndrome induced
by venlafaxine and fluoxetine: a case study in polypharmacy and
potential pharmacodynamic and pharmacokinetic mechanisms. Ann
Pharmacother 1998; 32:432-436
BLIER P, BERGERON R. The use of pindolol to potentiate antidepressant
medication. J Clin Psychiatry 1998; 59 (suppl 5):16-23, discussion
24-25
BODKIN JA, ZORRNBERG GL, LUKAS SE, COLE JO. Buprenorphine treatment
of refractory depression. J Clin Psychopharmacol 1995; 15:49-57
BODKIN JA, LASSER RA, WINES JD. Combining serotonin reuptake inhibitors
and bupropion in partial responders to antidepressant monotherapy.
J Clin Psychiatry 1997; 58:137-145
BONDOLFI G, CHAUTEMS C, ROCHAT B, BERTSCHY G, BAUMANN P. Non-response
to citalopram in depressive patients: pharmacokinetic and clinical
consequences of a fluvoxamine augmentation. Psychopharmacol 1996; 128:421-425
BONDOLFI G, LISSNER C, KOSE M, EAP CH, BAUMANN P. Fluoxetine augmentation
in citalopram non-responders: pharmacokinetic and clinical
consequences. Int J Neuropsychopharmacol 2000; 3:55-60
BORDET R, THOMAS P, DUPUIS B. Effect of pindolol on onset of action of paroxetine
in the treatment of major depression: intermediate
analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998; 155:1346-1351
BOUCKOMS AJ, MANGINI L. Pergolide: an antidepressant adjuvant for mood disorders?
Psychopharmacol Bull1993; 29:207-211
BOUHASSIRA M, ALLICAR MP, BLACHIER C, NOUVEAU A, ROUILLON F. Which patients
receive antidepressants? A 'real world' telephone study. J
Affect Disord 1998; 49:19-26
BROSCH S. Venlafaxine-fluoxetine interaction. J Clin
Psychopharmacol 1999; 19: 96
BRUIJN JA, MOLEMAN P, MULDER PG, VAN DEN BROEK WW. Comparison of 2
treatment strategies for depressed inpatients: imipramine and lithium
addition or mirtazapine and lithium addition.J Clin Psychiatry. 1998 Dec;59(12):657-63.
BYRNE S, ROTHSCHILD AJ. Psychiatrists' responses to failure of maintenance
therapy with antidepressants. Psychiatr Serv 1997; 48:835-837
CAPPIELLO A, MCDOUGLE CJ, DELGADO PL, MALISON RT, JATLOW P, CHARNEY DS,
HENINGER GR, PRICE LH. Lithium and desipramine versus desipramine alone in the
treatment of severe major depression: a preliminary study.
Int Clin Psychopharmacol 1998; 13:191-198
CARPENTER L, ZELJKO J, HALL J, RASMUSSEN S, PRICE L. Mirtazapine
augmentation in treatment of refractory depression. J Clin Psychiatry
1999; 60:45-49
CARPENTER L, JOCIC Z, HALL J, RASMUSSEN S, PRICE L. Mirtazapine augmentation
in the treatment of refractory depression. J Clin Psychiatry.
1999 Jan; 60:45-49
CARPENTER LL, YASMIN SPLH. A double blind, placebo-controlled study of
antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;
51:183-188
CIRAULO D, SHADER R. Fluoxetine drug-drug interactions: I. antidepressants and
antipsychotics. J Clin Psychopharmacology 1990; 10:48-50
COLONNA L, PETIT M, LEPINE JP. Bromocriptine in affective disorders
J Affect Disord 1979; 1:173-177.
COPPEN A. Potentiation of antidepressive effect of monoamine oxidase
inhibitor by tryptophan. Lancet 1963; 1:79-81
COPPEN A, BAILEY J. Enhancement of the antidepressant action of fluoxetine
by folic acid: a randomised, placebo controlled trial. J Affect
Disord 2000; 60:121-130
CORYELL W. Augmentation strategies for inadequate antidepressant response:
a review of placebo-controlled studies. Ann Clin Psychiatry
2000; 12:141-146
CRAIG R. Epidemiology of psychiatric medication use in patients
recovering from critical illness at a long-term acute-care facility. Mayo
Clin Proc 2001;76:
CRISMON ML, TRIVEDI M, PIGOTT TA, et al. The Texas Medication Algorithm
Project: Report of The Texas Consensus Conference Panel on
Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999; 60:142-156
CULLLEN M, MITCHELL P, BRODATY H, et al. Carbamazepine for treatment-resistant
melancholia. J Clin Psychiatry 1991; 52:472-476
DAVIDSON JR, MCLEOD MN, TURNBULL CD, MILLER RD.A comparison of phenelzine
and imipramine in depressed inpatients.J Clin Psychiatry. 1981
Oct;42(10):395-7.
DE LA GÁNDARA JJ, AGÜERA L, FERRE F, ROJO E, ROS S.
[Efficacy and safety issues in combining anti-depressants].
Actas Españolas de
Psiquiatría 2002; 30:75-84
DE LA GÁNDARA JJ, AGÜERA L, FERRE F, ROJO E, ROS S. Eficacia y seguridad
de la asociación de antidepresivos. Actas Españolas de
Psiquiatría, 2002; 30(2):75-84.
DE LA GANDARA J, AGÜERA L, FERRE F, ROJO E, ROS S. Asociaciones de antidepresivos
:resultados de una encuesta de opinión de psiquiatras
españoles. Psiquiatría Biológica 2002; 9:184-190
DE LA GÁNDARA JJ, AGÜERA L, FERRE F, ROJO E, ROS S. [Antidepressant combinations].
Monograph, Lab. Organon, 2002.
DE LA GÁNDARA JJ, AGÜERA L, FERRE F, ROJO E, ROS S. Asociaciones de antidepresivos.
Monografía, Lab. Organón, 2003.
DE LA GÁNDARA JJ, AGÜERA L, FERRE F, ROJO E, ROS S. Guia de utilización de las
Asociaciones de antidepresivos. Monografía, Lab. Organón, 2004.
DE LA GÁNDARA J.J (Editor): Antidepressant combinations: How and when to use them.
Acta Psychiatr Scand 2005: 112 (Supp 428) 2005.
DE LA GÁNDARA J, AGÜERA L, ROJO JE, ROS S. Depresión resistente. Guía de utilización
de las asociaciones de antidepresivos. In press. 2005
DE LA GÁNDARA J.J., AGÜERA L.F., ROJO J.E., ROS S. Tácticas y estrategias de utilización
de las asociaciones de antidepresivos. Grupo
GEAA, Lab. Organón, 2005.
DE LA GÁNDARA J, AGUERA L, ROJO JE, ROS S, DE PEDRO JM. Use of antidepressant
combinations: which, when and why? Results of a Spanish
survey. Acta Psychiatr Scand Suppl. 2005;(428):32-6.
DE LA GÁNDARA J, ROJO JE, ROS S, AGUERA L, DE PEDRO JM. Neuropharmacological basis
of combining antidepressants. Acta Psychiatr Scand
Suppl. 2005;(428):11-3, 36.
DE LA GÁNDARA J. J. Caso clínico: Asociación de antidepresivos de segundo
nivel (mirtazapina más duloxetina. Psicotropías, 1, 2007.
DE MONTIGNY C, GRUNBERG F, MAYER A, DESCHENES JP. Lithium induces rapid relief
of depression in tricyclic antidepressant drug non-responders.
Br J Psychiatry 1981; 138:252-256
DEBATTISTA C, SOLVASON HB, FLORES BH. Modafinil as an adjunctive agent in the treatment
of fatigue and hypersomnia associated with
depression. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology;
Dec 10-14, 2000; San Juan, Puerto Rico.
DEVARAJAN S, DURSUN SM. Paroxetine/bupropion combination in treatment-resistant
depression (letter). Can J Psychiatry 2000; 45:489-490
DIMELLIS D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine.
World J Biol Psychiatry 2002; 3:167
DIMITRIOU EC, DIMITRIOU CE. Buspirone augmentation of antidepressant
therapy. J Clin Psychopharmacol 1998; 18:465-469
DINAN TG. Lithium augmentation in sertraline-resistant depression: a
preliminary dose-response study. Acta Psychiatr Scand 1993; 88:300-301
DINAN TG, LAVELLE E, COONEY J, et al. Dexamethasone augmentation in
treatment-resistant depression. Acta Psychiatr Scand 1997; 95:58-61
DINGEMANSE J. An update of recent moclobemide interaction data.Int Clin
Psychopharmacol. 1993 Jan;7(3-4):167-80.
DITTMANN RW, LINDEN M, OSTERHEIDER M, SCHAAF B, OHNMACHT U, WEBER HJ.
Antidepressant drug use: differences between psychiatrists and general practitioners. Results
from a drug utilization observation study with fluoxetine. Pharmacopsychiatry 1997; 30:28-34
DORDING CM. Antidepressant augmentation and combinations. Psychiatr Clin North Am 2000; 23:743-755
DORDING C, MISCHOULON, PETERSEN T, et al. The pharmacologic management of SSRI
-induced side effects: A survey of psychiatrists. Ann Clin
Psychiatry 2002;14:143-146
DORNSEIF BE, DONLOP SR, POTIN JH. Effect of dose escalation after low-dose
fluoxetine therapy . Psychopharmacol Bull 1989; 25:71-79
DUNNER D, AMSTERDAM JD, SHELTON RC. Adjunctive zyprasidone in treatment resistant
depression: a pilot study. NR 238. Presented at the156th APA Annual Meeting, San Francisco, Ca, May 17-22, 2003
FAVA M, ROSENBAUM JF, MCGRATH PJ, STEWART JW, AMSTERDAM JD, GRAHAM PM. Combined
mianserin and tranylcypromine. Br J Psychiatry 1988;153:415-417
FAVA M, ROSENBAUM JF, COHEN L, et al. High-dose fluoxetine in the treatment of depressed
patients not responsive to a standard dose of
fluoxetine. J Affect Disord 1992; 25:229-234
FAVA M, ROSENBAUM JF, MCGRATH PI, STEWART JW, AMSTERDAM JD, QUITKIN FM. Lithium and tricyclic
augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled
study. Am J Psychiatry 1994, 151:1372-1374
FAVA M. New approaches to the treatment of refractory depression.
J Clin Psychiatry 2000;61 Suppl 1:26-32
FAVA M. Augmentation and combination strategies in treatment resistant depression.
J Clin Psychiatry 2001; 62 (supp18):4-11
FAVA M, ALPERT J, NIERENBERG AA, et al. Double-blind study of high-dose
fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders
and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22:379-387
FAVA M. Step changes during long-term treatment with antidepressants. NR 17C. Presented
at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003
FAVA M, RUSH J, MADHUKAR H, et al. Background and rationales for the sequenced
treatment alternatives to relieve depression (STARD*D) Study. Psychiat Clin N America 2003; 26:457-494
FAWCETT J, KRAVITZ HM. Treatments of refractory depression. In: SCHATZBERG AF, ed.
Common Treatment Problems in Depression. American Psychiatry Press, Washington, 1985
FAWCETT J, KRAVITZ HM, ZAJECKA J, SCHAFF MR. CNS stimulant potentiation of monoamine oxidase
inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991; 11:127-132
FEIGHNER JO, HERBSTEIN J, DAMLOUJI N. Combined MAOI, TCA, and direct stimulant therapy
of treatment-resistant depression. J Clin Psychiatry 1985, 46:206-209
FEIGHNER JP, BOYER WF, TYLER DL, NEBORSKY RJ. Adverse consequences of fluoxetine-MAOI
combination therapy.J Clin Psychiatry. 1990 Jun;51(6):222-5.
FEIN S, PAZ V, RAO N, LAGRASSA J. The combination of lithium carbonate and an MAOI in
refractory depressions. Am J Psychiatry 1988; 145:249-250
FISCHER P, TAUSCHER J, KUEFFERLE B, KASPER S. Weak antidepressant response after buspirone
augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin
Psychopharmacol. 1998; 13: 83-86
FREEDMAN SJ, ROSENBAUM JF, FAVA M, et al. How often do the psychiatrics raise the dose
when SSRIs do nor work?. NR 128 [7]. 1999. Washington. 152nd Annual meeting of the
American Psychiatric Association. Ref Type: Conference Proceeding
FREEDMAN SJ, FAVA M, KIENKE AS, WHITE CN, NIERENBERG AA, ROSENBAUM JF. Partial response,
nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a
survey of current "next-step" practices. J Clin Psychiatry 2000; 61:403-408.
FREYHAN FA. Contributions to the definitions of therapy-resistant depressions. Pharmacopsychiatry 1974; 7:70-75
GANDER DR. Treatment of depressive illnesses with combined antidepressants. Lanc
GASTö C, POLAINO A, DE LAS HERAS J, OBIOLS J, DOMÉNECH E. Depresiones
Resistentes. Barcelona. Ed. Mayo, 1995
GHADIRIAN AM, ENGLESMANN F, DHAR V, et al. The psychotropic effects of inhibitors
of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995; 37:369-375
GIBERT RAHOLA J. Lo que siempre quiso saber de los psicofármacos…y nunca se atrevió
a preguntar. Gibert J Eds. Aula Medica. Madrid. 2000
GOLDBERG SC, TILLEY DH, FRIEDEL RO, et al. A survey of psychiatrists practices
related to the use of tricyclic antidepressants. Hosp Community Psychiatry 1986; 37:1247-1251
GOMEZ JM, TEIXIDO C. Combined treatment with venlafaxine and tricyclic antidepressants
in depressed patients who had partial response to clomipramine or imipramine: initial
findings. J Clin Psychiatry 2000; 61:285-289
GONUL A.S, AKDENIZ F, DONAT O, VAHIP S. Selective serotonin reuptake inhibitors combined
with venlafaxine in depressed patients who had partial response to venlafaxine: four cases.
Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27:889-891
GOODWIN R, PRANGE A, POST R, MUSCETTOLA G, LIPTON MA. Potentiation of antidepressant effects
by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982; 139:34-38
GORMAN JM. Mirtazapine: clinical overview.J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8.
GREENBLATT DJ, VON MOLTKE LL;HARMATZ JS;SHADER RI. Drug interactions with newer
antidepressants: role of human cytochromes P450. J Clin Psychiatry. 1998; 59(suppl15) 19-27
GREGOR KJ, RILEY JA, DOWNING DK. Concomitant use of anxiolytics and hypnotics with
selective serotonin reuptake inhibitors. Clin Ther 1996; 18:521-527
GREGOR KJ, WAY K, YOUNG CH, JAMES SP. Concomitant use of selective serotonin reuptake
inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does
it really happen? J Affect Disord 1997; 46:59-67
GUPTA S. Effect of citalopram on blood desipramine levels. Prim Care Companion J Clin Psychiatry 2002; 2:8
GUZE B, BAXTER L, REGO J. Refractory depression treatment with high doses of a monoamine
oxidase inhibitor. J Clin Psychiatry 1987; 48:31-32
HALE A, PROCTER A, BRIDGES P. Clomipramine, tryptophan and lithium in combination for
resistant endogenous depression: seven case studies. Br. J. Psychiatry 1987; 151:213-217
HANJE AJ, PELL LJ, VOTOLATO NA, FRANKEL WL, KIRKPATRICK RB. Case report: fulminant hepatic
failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol. 2006 Jul;4(7):912-7
Epub 2006 Jun 22.
HARKIN A, KELLY JP, MCNAMARA M, CONNOR TJ, DREDGE K, REDMOND A, LEONARD BE. Activity
and onset of action of reboxetine and effect of combination with sertraline in an animal
model of depression.Eur J Pharmacol. 1999 Jan 8;364(2-3):123-32.
HASKOVEC L, RYSANEK K. Action of reserpine in imipramine-resistant depressive patients. Psychopharmacol 1967; 11:18-30
HATTERER JA, GORMAN JM. Thyroid function in refractory depression. In: ROOSE SP, GLASSMAN AH,
eds. Treatment Strategies for Refractory Depression. American Psychiatry Press, Washington DC, 1990
HAWLEY CJ, QUICK SJ, RATNAM S, PATTINSON HA, MCPHEE S. Safety and tolerability of combined
treatment with moclobemide and SSRIs: asystematic study of 50 patients. Int Clin Psychopharmacol.
1996 Sep;11(3):187-91.
HAYKAL RF, AKISKAL HS. Bupropion as a promising approach to rapid cycling bipolar II patients.
J Clin Psychiatry 1990; 51:450-455
HENINGER GR, CHARNEY DS, STERNBERG DE. Lithium carbonate augmentation of antidepressant
treatment. An effective prescription for treatment-refractory depression. Arch Gen
Psychiatry 1983; 40:1335-1342
HERRERO L. Trastornos depresivos en la práctica clínica [Depressive disorders in clinical settings].
Newsletter Psiq Hoechst Ibérica 1982.
HIRSCHFELD R, MONTGOMERY S, AGUGLIA E, et al. Partial response and non-response to
antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry
2002; 63:826-836
IOSIFESCU D. The antidepressant efficacy of T3 augmentation treatment in MDD is
associated with increased brain energy metabolism. Poster 78. ACNP 42nd Annual Meeting.
San Juan, Puerto Rico, 2003.
ISHAK WW, RAPAPORT MH, GOTTO JG. The effectiveness of atypical antipsychotic medications
in depressive disorders. Curr Psychiatry Rep 2004; 6:422-424
IZUMI T, INOUE T, KITAGAWA N, et al. Open pergolide treatment of tricyclic and heterocyclic
antidepressant-resistant depression. J Affect Disord 2000; 61:127-132
JACOBSEN FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52:217-220
JANUEL D, POIRIER MF, D’ALCHE-BIREE F, DIB M, OLIE JP. Multicenter double-blind randomized parallel
-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium
carbonate(750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar
major depression. J. Affect Disord 2003; 76:191-200.
JARECKI H J. Comnbined amitryptiline and phenerlzine poisoning. Am J Psychiatry 1963:120:189.
JOFFE RT, LEVITT AJ, BAGBY RM, MACDONALD C, SINGER W. Predictors of response to lithium and
triiodothyronineaugmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993; 163:574-578
JOFFE RT, SCHULLER DR. An open study of buspirone augmentation of serotonin reuptake
inhibitors in refractory depression. J Clin Psychiatry 1993; 54:269-271
JOFFE RT, SINGER W, LEVITT AJ, MACDONALD C. A placebo-controlled comparison of lithium and
triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression
.Arch Gen Psychiatry 1993; 50:387-393.
JOFFE RT, BAKISH D. Combined SSRI-moclobemide treatment of psychiatric illness.
J Clin Psychiatry. 1994 Jan;55(1):24-5.
JOFFE RT, LEVITT AJ. Antidepressant failure: augmentation and substitution. J Psychiatry Neurosci 1995; 20:7-9
JOHNSON FN. Lithium augmentation therapy. Rev Contemp Pharmacother 1991; 2:1-52
KATONA CL, ABOU-SALEH MT, HARRISON DA, et al. Placebo-controlled trial of lithium
augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80-86
KELSEY JE. Treatment Strategies in achieving remission in major depressive disorder.
Acta Psychiatr Scand 2002;106 (suppl 415):18-23
KELLER MB. The long-term treatment of depression. J Clin Psychiatry. 1999;60 Suppl 17:41-5; discussion 46-8.
KENNEDY SH, MCCANN SM, MASELLIS M, et al. Combining bupropion SR with venlafaxine, paroxetine,
or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction
effects. J Clin Psychiatry 2002; 63:181-186
KHAN MC, WICKHAM AE, REED JV. Lithium versus placebo in acute depression: a clinical
trial. Int Clin Psychopharmacol 1987; 2:47-54
KIELHOLZ P, TERZANI S, GASPAR M, et al. Treatment for therapy resistant depression.
Int Pharmacopsychiatry 1979; 14:94-100
KIELHOLZ P. Treatment for therapy-resistant depression. Psychopathol 1986;19 suppl 2:194-200
KLAIBER EL, BROVERMAN DM, VOGEL W, KOBAYASHI Y. Estrogen therapy for severe persistent depression
in women. Arch Gen Psychiatry 1979; 36:550-554
KLYSNER R, GEISLER A. Rapid dowregulation of cerebral B-adrenoreceptors by combined treatment whit
imipramine and mianserine. Advances in neuropsychiatry and psychopharmacology: refractory depression.
Jay D, ed. New York, Raven Press, 1991, 109-113
KLYSNER R, GEISLER A. Rapid dowregulation of cerebral B-adrenoreceptors by combined treatment whit
imipramine and mianserine. Advances in neuropsychiatry and psychopharmacology: refractory depression.
Jay D, ed. New York, Raven Press, 1991, 109-113
KOGEORGOS J, KOTROTSOU M, POLONIFIS N. Modafinil as augmentation of antidepressant therapy. Eur
Neuropsychopharmacol 2002; 12:S211-212
KONIG F, WOLFERSDORF M, LOBLE M, WOSSNER S, HAUGER B.Trimipramine and maprotiline plasma levels
during combined treatment withmoclobemide in therapy-resistant depression. Pharmacopsychiatry.
1997 Jul;30(4):125-7.
KONIG F, WOLFERSDORF M. Combination therapy using moclobemide with tricyclic and tetracyclic
antidepressants to treat therapy-resistant depression. Pharmcopsychiatry 1997; 30:93-96
KOTZAN J, MACLEAN R, WADE W, et al. Prevalence and patterns of concomitant use of selective
serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort.
Clin Ther 2002; 24:237-248
KUSHNIR SL. Lithium-antidepressant combinations in the treatment of depressed,
physically ill geriatric patients. Am J Psychiatry 1986; 143:378
LAFONT-LAPEZ L, LAUZEL JP, COUSIN R et al. Étude de la potentialisation de deux
antidépresseurs entre eux. Inform Psychiatr 1986; 62:1145-1158
LAM RW, WAN DC, COHEN NL, KENNEDY SH. Combining antidepressants for treatment-resistant
depression: a review. J Clin Psychiatry 2002; 63;685-693
LANDEN M, BJORLING G, AGREN H, FAHLEN T. A randomized, double-blind placebo-controlled trial
of buspirone in combination with an SSRI in patients with treatment-refractory depression.
J Clin Psychiatry 1998; 59:664-668
LANDEN M, ERIKSSON E, AGREN H, FAHLEN T. Effect of buspirone in sexual dysfunction in depressed
patients treated with selective serotonin reuptake inhibitor. J Clin Psychopharmacol 1999; 19:268-271
LATTANZI L, DELL OSSO L, CASSANO P, et al. Pramipexole in treatment-resistant depression: a 16/week
naturalistic study. Bipolar Disord 2002; 4:307-314
LAURITZEN L, CLEMMESEN L, KLYSNER R, LOLDRUP D, LUNDE M, SCHAUMBURG E, WAARSTS, BECH P.
Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry 1992; 25:182-186
LAURITZEN L, BENDSEN BB, VILMAR T, BENDSEN EB, LUNDE M, BECH P. Post-stroke depression: combined
treatment with imipramine or desipramine and mianserin. A controlled clinical study.
Psychopharmacol (Berl) 1994; 114:119-122
LAVRETSKY H, KIM MD, KUMAR A, REYNOLDS CF 3RD. Combined treatment with methylphenidate and
citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003; 64:1410-1414
LEVINE J, GONZALVES M, BABUR I. Inositol 6gm daily may be effective in depression but not in
schizophrenia. Human Psychopharmacol1993; 8:49-53
LEVITT AJ, JOFFE RT, KAMIL R, MCINTYRE R. Do depressed subjects who have failed both fluoxetine
and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 1999; 60:613-616
LÓPEZ-IBOR ALIÑO JJ. La Monoclomipramina en enfermos psiquiátricos resistentes a otros tratamientos
[Monoclomipramine in psychiatric patients resistant to other treatments]. Actas Luso Españolas
Neurología Psiquiátrica 1971; 26:119-147
LÓPEZ-MUÑOZ F, RUBIO G, ÁLAMO C, GARCÍA-GARCÍA P, PARDO A. Reboxetine addition in patients
with mirtazapine-resistant depression: a case series. Clin Neuropharmacol. 2006. Jul-Aug; 29 (4):192-6.
LOZANO M, JIMENEZ D. Tratamiento combinado con antidepresivos heterocíclicos y paroxetina
en la depresión resistente. Psiquiatría Biológica 1994; 1:126-129
MANCINI C, VAN AMERIGEN M, FARVOLDEN P. Does SSRI augmentation with antidepressants that
influence noradrenegic function resolve depression in obsessive-compulsive disorder?
J Affect Disord 2002; 68: 59-65.
MARSHALL RD, LIEBOWITZ M. Paroxetine/bupropion combination treatment for refractory
depression (letter). J Clin Psychopharmacol 1996; 16:80-81
MARTÍN, L.M. Tesis Doctoral, Barcelona, 2005.
MCINTYRE R, MULLER A, MANCINI D, SILVER E. What to do if an initial antidepressant fails?
Can Fam Physician 2003; 49:449-457
MCMANUS P, MANT A, MITCHELL P, BIRKETT D, DUDLEY J. Co-prescribing of SSRIs and tricyclic
antidepressants in Australia: how often does it occur and who is doing it? Br J Clin Pharmacol 2001; 51:93-98
MEDHUS A, HESKESTAD S, TJEMSLAND L. Mianserin added to tricyclic antidepressant in depressed patients
not responding to a tricyclic antidepressant alone. A randomized, placebo-controlled, double-blind
study. Nor J Psychiatry 1994; 48:355-358
MEDINA A, MORENO M. La carbamacepina en el tratamiento de las depresiones resistentes
[Carbamazepine in treating resistant depressions]. Rev Depto Psiq Fac Med Barc 1985; 12:287-292
MENZA MA, KAUFMAN KR, CASTELLANOS AM. Modafinil augmentation of antidepressant treatment
in depression. J Clin Psychiatry 2000; 61:378-381
MICHELSON D, BANCROFT J, TARGUM S, KIM Y, TEPNER R. Female sexual dysfunction associated
with antidepressant administration: a randomised, placebo-controlled study of pharmacologic
intervention. Am J Psychiatry 2000, 157:239-243
MOLLER HJ. Are all antidepressants the same? J Clin Psychiatry 2000; 61 Suppl 6:24-28
MORENO F, GELENBERG AJ, BACHAR K, DELGADO PL. Pindolol augmentation of treatment-resistant
depressed patients. J Clin Psychiatry 1997; 58:437-439
MURPHY BEP, DHAR V, GHADIRIAN AM, CHOUINARD G, KELLER R. Response to steroid suppression in
major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991; 11:121-126
NELSON JC, MAZURE CM, BOWERS MB JR, JATLOW PL. A preliminary, open study of the combination of
fluoxetine and desimpramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-307
NELSON JC, PRICE LH. Lithium or desipramine augmentation of fluoxetine treatment. Am J Psychiatry 1995; 56:338-343
NELSON JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61:13-19
NELSON C. Managing treatment-resistant major depression. J Clin Psychiatry 2003;
64 (suppl 1): 5-12.
NEMETS B, MISHORY A, LEVINE J, BELMAKER RH. Inositol addition does not improve depression in
SSRI treatment failures. J Neural Transm 1999; 106:795-798
NEUVONEN PJ, POHJOLA-SINTONEN S, TACKE U, VUORI E. Five fatal cases of serotonin syndrome
after moclobemide-citalopram or moclobemide-clomipramine overdoses.
Lancet. 1993 Dec 4;342(8884):1419.
NICHOL M, STIMMEL G, LANGE SC. Factors predicting the use of multiple psychotropic medications.
J Clin Psychiatry 1995; 56:60-66
NIERENBERG AA. Treatment choice after one antidepressant fails: A survey of northeaster psychiatrists.
J Clin Psychiatry 1991; 52:383-385
NIERENBERG AA, FEIGHNER JF, RUDOLPH R, COLE JO, SULLIVAN J. Venlafaxine for treatment-resistant
unipolar depression. J Clin Psychopharmacol 1994; 14:419-423
NIERENBERG AA, PAPAKOSTAS GI, PETERSEN T, et al. Lithium augmentation of nortriptyline for
subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003; 23:92-95
NOLEN WA, VAN DE PUTTE J, DIJKEN WA, KAMP JS. L-5HTP in depression resistant to
reuptake inhibitors.An open comparative study with tranylcypromine.
Br J Psychiatry 1985; 147:16-22
NOVAC A. Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with
GAD. J Clin Psychiatry 1992; 53:67
O´BRIEN S, MCKEON P,O´REGAN M. The efficacy and tolerability of combined antidepressant treatment
in different deprssive subgroup. Br J Psychiatry 1993; 162:363-368.
O’DWYER AM, LIGHTMAN SL, MARKS MN, CHECKLEY SA. Treatment of major depression with metyrapone
and hydrocortisone. J Affect Disord 1995; 33:123-128
OSHIMA A, HIGUCHI T, FUJIWARA Y, et al. Questionnaire survey on the prescribing practice of
Japanese psychiatrists for mood disorders. Psychiatry Clin Neurosci 1999; 53 (Suppl):S67-S72
OSTROFF RB, NELSON JC. Risperidone augmentation of selective serotonin reuptake inhibitors
in major depression. J Clin Psychiatry 1999; 60:256-259
OWEN JR, NEMEROFF CB. New antidepressants and the cytochrome P450 system: focus
on venlafaxine, nefazodone and mirtazapine. Depression and Anxiety. 1998, 7suppl 1: 24-32
PALLANTI S, QUERCIOLI L, BRUSCOLI M. Response acceleration with mirtazapine augmentation
of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot
study.J Clin Psychiatry. 2004 Oct; 65(10):1394-9.
PAPAKOSTAS GI, PETERSEN TJ, NIERENBERG AA, et al. Ziprasidone augmentation of selective
serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
J Clin Psychiatry 2004; 65:217-221
PAYKEL ES. Epidemiology of refractory depression. In: NOLEM NA et al, eds. Refractory Depression
Current strategies and future directions. John Wiley & Sons,
Chichester, 1994, 3-17
PÉREZ V, GILABERTE I, FARIES D, ALVAREZ E, ARTIGAS F. Randomized, double-blind, placebo-controlled
trial of pindolol in combination with fluoxetine antidepressant treatment.
Lancet 1997; 349:1594-1597
PEREZ V, SOLER J, PUIGDEMONT D, ALVAREZ E, ARTIGAS F. A double-blind, randomized, placebo-controlled
trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitor.
Grup de Recerca en Trastorns Afectius [Affective Disorder Working Group]. Arch Gen Psychiatry,
1999; 56:375-379
POLDINGER W. [Recent aspects of biological treatment of depression]. Ther Umsch 1990; 47:233-240
POPE HG. Testosterone gel supplementation for men with refractory depression: a randomized,
placebo-controlled trial. Am J Psychiatry 2003; 160:105-111
POSTERNAK M, ZIMMERMAN MA. Switching versus augmentation: a prospective, naturalistic comparison
in depressed treatment resistant patients. J Clin Psychiatry 2001; 62:135-142
PRANGE AJ JR, WILSON IC, RABON AM. Enhancement of imipramine antidepressant activity by thyroid
hormone. Am J Psychiatry 1969, 126:39-51
PRANGE AJ. Estrogen may well affect response to antidepressant. JAMA 1972; 219:143-144
PRANGE AJ Jr. Novel uses of thyroid hormones in patients with affective disorders.
Thyroid 1996; 6:537-543
PRESKORN SH, BEBER JH, FAUL JC, HIRSCHFELD RM. Serious adverse effects of combining
fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990; 147:532
PRESKORN SH. Targeted pharmacoterapy in depresion management: pharmacokinetics of fluoxetine,
paroxetine and sertraline. Int Clin Psychopharmacol 1994 ; 9(suppl 3): 13-19
PRESKORN S. Reducing the risk of drug-drug interactions: A goal of rational drug development
J Clin Psychiatry 1996; 57 suppl 1:3-6
PRICE LH, CHARNEY DS, HENINGER GR. Reserpine augmentation of desipramine in refractory
depression: clinical and neurobiological effects. Psychopharmacology 1987; 92:431-437
PRICE LH. Pharmacological strategies in refractory depression. In: TASMAN A, GOLDFINGER SM,
KAUFMAN CA, eds. American Psychiatric Press Review of Psychiatry, Vol 9. American Psychiatric
Press, Washington DC, 1990: 116-131
PURI BK, COUNSELL SJ, HAMILTON G, RICHARDSON AJ, HORROBIN DF. Eicosapentaenoic acid in
treatment-resistant depression associated with symptoms remission, structured brain changer
and reduced neuronal phospholipid turnover. Int Clin Pract 20
QUITKIN FM. The importance of dose in prescribing antidepressants. Br J Psychiatry 1985; 147:593-597
QUITKIN FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major
depression: a double-blind, controlled study. Am J Psychiatry 1994; 151: 1372-1374
RANJAN R, MELTZER HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic
depression. Biol Psychiatry 1996, 40:253-258
RAVARIS CL, BRINCK-JOHNSEN C, ELLIOT B. Clinical use of ketoconazole in hypocortisoluric
depressives. Biol Psychiatry 1994; 35:679
RAZANI J, WHITE KL, WHITE J ET AL. The safety and efficacy of combined amitryptiline and
tranylcipromine antidepressant treatmen. Arch Gen Psychiatry 1983;40:657-661
REIMHERR FW, WOOD DR, BYERLY B. Characteristics of responders to fluoxetine.
Psychopharmacol Bull 1984; 20:70-73
RICHELSON E. Pharmacokinetic drug interactions of new antidepressants: A review of
the effects on the metabolism of other drugs. Mayo Clin Proc ; 1997; 72: 835-847
RICHELSON E. Pharmacology of Antidepressants. Mayo Clin Proc 2001; 76:511-527
RIISE IS, HOMLM P. Concomitant isocarboxacid/mianserin treatment of major depressive disorder.
J Affect Disord 1984; 6:175-179
RIZZITELLI F, SPINA A. Imipramine-desipramine association in depressive syndromes:
EEG study during spontaneous sleep. Acta Neurol 1973;28: 580-587
ROCHA FL, HARA C. Lamotrigine augmentation in unipolar depression.
Int Clin Psychopharmacol 2003; 18:97-99
ROJO JE, ROS S, AGUERA L, DE LA GANDARA J, DE PEDRO JM. Combined antidepressants:
clinical experience. Acta Psychiatr Scand Suppl. 2005;(428):25-31, 36.
RONSON R, OFFMAN HJ, JOFFE RT, NAYLOR CD. Triiodothyronine augmentation in the
treatment of refractory depression. A meta-analysis. Arch
Gen Psychiatry 1996; 53:842-848
ROS S, AGUERA L, DE LA GÁNDARA J, ROJO JE, DE PEDRO JM. Potentiation strategies
for treatment-resistant depression. Acta Psychiatr
Scand Suppl. 2005;(428):14-24, 36.
ROSHOLM JU, HALLAS J, GRAM LF. Concurrent use of more than one major psychotropic
drug (polypsychopharmacy) in out-patients--a prescription database study.
Br J Clin Pharmacol 1994; 37:533-538
RUBIO G, SAN L, LOPEZ-MUÑOZ F, GARCÍA-GARCIA P, ÁLAMO C. Tratamiento de combinación con
reboxetina en pacientes con depresión mayor no respondedores o con respuesta parcial a
inhibidores selectivos de la recaptación de serotonina. Actas Esp Psiquiatr 2003; 31:315-324
RUSH AJ, CRISMON ML, TOPRAC MC, et al. Consensus guidelines in the treatment of major
depressive disorder. J Clin Psychiatry 1998; 59 suppl 20:73-84
RUSH AJ, FAVA M, WISNIEWSKI SR, LAVORI PW, et al. Sequenced treatment alternatives
to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25:119-142.
SARGANT W. Combining the antidepressant drugs. The Lancet 1963; 15:634-635
SCHAMAUS M, KAPFHAMMER HP, MEYR P, HOFF P. Combined MAO-inhibitor and tri(tetra)cyclic
antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol
Biolog Psychiatry 1988;12:523-532
SCHMAUSS M, LAAKMANN G, DIETERLE D. Effects of alpha 2-receptor blockade in addition to
tricyclic antidepressants intherapy-resistant depression.J Clin Psychopharmacol.
1988 Apr;8(2):108-11.
SCHUCKIT M, ROBINS E, FEIGHNER J. Tricyclic antidepressants and monoamine oxidase inhibitors
.Arch Gen Psychiatry. 1971 Jun;24(6):509-14.
SCHULBERG H, KATON WJ, SIMON G, RUSH AJ. Best clinical practice guidelines for managing
major depression in primary medical care. J Clin Psychiatry 1999; 60 suppl 7:19-26
SCHWARTZ TL, LESO L, BEALE M, AHMED R, NAPRAWA S. Modafinil in the treatment of depression
with severe comorbid medical illness. Psychosomatics 2002; 43:336-337
SCHWEIZER E, RICKELS K, AMSTERDAM JD, FOX I, PUZZUOLI G, WEISE C. What constitutes an adequate
antidepressant trial of fluoxetine? J Clin Psychiatry 1990; 51:8-11
SCOTT J. Epidemiology, demography and definitions. In: ECCLESTON D, ed. Resistant
Depressions. CNS (Clinical Neuroscience) Publications, Oxford, 1991, 1-12
SETH R, JENNINGS AL, BINDMAN J, PHILLIPS J, BERGMANN K. Combination treatment with
noradrenalin and serotonin reuptake inhibitors in resistant depression.
Br J Psychiatry 1992; 161:562-565
SETHNA ER. A study of refractory cases of depressive illness and their response
to combined antidepressant treatment. Br J Psychiat 1974; 124:265-272
SHAPIRA B, OPPENHEIM G, ZOHAR J, SEGAL M, MALACH D, BELMAKER RH. Lack of efficacy
of estrogen supplementation to imipramine in resistant female depressive.
Biol Psychiatry 1985; 20:576-579
SHELTON RC, TOLLEFSON GD, TOHEN M, et al. A novel augmentation strategy for treating
resistant major depression. Am J Psychiatry 2001; 158:131-134
SHELTON RC. The use of antidepressants in novel combination therapies.
J Clin Psychiatry 2003; 64 suppl 2:14-18
SHERGILL SS, KATONA C. Pharmacological choices after one antidepressant fails: a
survey of UK psychiatrists. J Affect Disord 1997; 43:19-25
SILVERSTONE T. Response to bromocriptine distinguishes bipolar from unipolar depression.
Lancet 1984; 1:903-904
SMALL JC. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26:25-36
SNOWDON J, BRAITHWAITE R. Letter: Combined antidepressant medication.
Br J Psychiatry. 1974 Dec;125:610-1.
SOLER-INSA PA, GASCÓN J. RTM-II. Trastornos afectivos. In: Recomendaciones
Terapéuticas en los Trastornos Mentales. Masson, Barcelona, 1999
SOUTULLO CA, MCELROY SL, KECK PE JR. Hypomania associated with mirtazapine
augmentation of sertraline. J Clin Psychiatry 1998; 59:320
SPIER SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety 1998; 7:73-75
SPIKER DG, PUGH DD.Combining tricyclic and monoamine oxidase inhibitor antidepressants
.Arch Gen Psychiatry. 1976 Jul;33(7):828-30.
SPILMANN M, FAVA M. S-adenosylmethionine (ademetionine) in psychiatric disorders:
historical perspective and current status. CNS Drugs 1996; 6:416-425
SPINA A. The association of imipramine and desipramine in the treatment of depressions.
Acta Neurol 1971; 26:490-495
SPORN J, GHAEMI SN, SAMBUR MR, et al. Pramipexole augmentation in the treatment of unipolar
and bipolar depression: a retrospective chart review.
Ann Clin Psychiatry 2000; 12:137-140
STAHL SM. Psychopharmacology of antidepressants. Martín Dunitz, London, 1997
STAHL SM. Natural estrogen as an antidepressant for women.
J Clin Psychiatry 2001; 62:404-405
STEIN G, BERNADT M. Lithium augmentation therapy in tricyclic resistant depression:
a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634-640
STOLL AL, PILLAY SS, DIMOND L, WORKUM SB, COLE JO. Methylphenidate augmentation of
serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996; 67:72-76
STOLL AL, RUETER S. Treatment augmentation with opiates in severe and refractory
major depression (letter). Am J Psychiatry 1999; 156:2017
STOLL AL, SEVERUS WE, FREEMANN MP, et al. Omega-3 fatty acids in bipolar disorder:
a preliminary double-blind, placebo-controlled trial.
Arch Gen Psychiatry 1999; 56:407-412
TALEB M, GORWOOD P, BOULEAU JH, ROUILLON F. The tolerability and efficacy of
combined antidepressant therapy: literature review.
Encephale 1996; 22:450-460
TANUM LH. Combination treatment with antidepressants in refractory depression.
Int Clin Psychopharmacol 1994; 9 Suppl 2:37-40
TARIOT PN, MURPHY DL, SUNDERLAND T, MUELLER EA, COHEN RM. Rapid antidepressant
effect of addition of lithium to tranylcypromine.
J Clin Psychopharmacol 1986; 6:165-167
TAYLOR D. Selective serotonin reuptake inhibitors and tricyclic antidepressants
in combination. Interactions and therapeutic uses. Br J Psychiatry.
1995 Nov; 167(5):575-80.
THASE EM, RUSH J. When at first you don’t succeed: sequential strategies for
antidepressant nonresponders. J Clin Psychiatry 1997; 58 suppl 13:23-29
THASE ME, HOWLAND RH, FRIEDMAN ES. Treating antidepressant nonresponders with
augmentation strategies: An overview. J Clin Psychiatry
1998; 59 (Suppl 5):5-12
THASE ME. Redefining antidepressant efficacy toward long-term recovery.
J Clin Psychiatry. 1999;60 Suppl 6:15-9
THASE ME, FRIEDMAN ES, HOWLAND RH. Venlafaxine and treatment-resistant depression.
Depress Anxiety. 2000;12 Suppl 1:55-62. Review.
THASE ME, FRIEDMAN ES, BERMAN SR, FASICZKA AL, LIS JA, HOWLAND RH, SIMONS AD
. Is cognitive behavior therapy just a 'nonspecific' intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior
therapy or supportive counseling and pill placebo.
THASE ME, FRIEDMAN ES, HOWLAND RH. Management of treatment-resistant depression:
psychotherapeutic perspectives. J Clin Psychiatry.
2001;62 Suppl 18:18-24. Review.
THASE M, ENTSUAH R, RUDOLPH R. Remission rates during treatment with venlafaxine
or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241
TOME MB, ISAAC MT. Paroxetine and pindolol: a randomised trial serotoninergic
autoreceptor blockade in the reduction of antidepressant latency.
Int Clin Psychopharmacol 1997; 12:81-89
VANDEL S, BERTSCHY G, BAUMANN P, BOUQUET S, BONIN B, FRANCOIS T, SECHTER D,
BIZOUARD P. Fluvoxamine and fluoxetine: interaction studies with amitriptyline,
clomipramineand neuroleptics in phenotyped patients.Pharmacol Res. 1995 Jun;31(6):347-53.
VAUGHAN DA. Interaction of fluoxetine with tricyclic antidepressants.
Am J Psychiatry. 1988 Nov;145(11):1478.
VALLEJO J. Alternativas terapéuticas en las depresiones resistentes
[Therapeutic alternatives for treatment-resistant depressions].
Farmacología del SNC, 1991, 5:85-98
VALLEJO J, URRETAVIZCAYA M. Tratamiento farmacológico de las depresiones resistentes.
In: Vallejo J, ed. Arboles de Decisión de Psiquiatría,
Jims, Barcelona, 1999
VALLEJO J, GASTÓ C. Trastornos afectivos: ansiedad y depresión
[Affective disorders: anxiety and depression].
Editorial Masson, 2000
VANDEL S, BERTSCHY G, BAUMANN P, et al. Fluvoxamine and fluoxetine:
interaction studies with amitriptyline, clomipramine and neuroleptics in
phenotyped patients. Pharmacol Res 1995; 31:347-353
WEILBURG JB, ROSENBAUM JF, BIEDERMAN J, SACHS GS, POLLACK MH, KELLY K.
Fluoxetine added to non-MAOI antidepressants converts nonresponders to
responders: a preliminary report. J Clin Psychiatry 1989; 50:447-449
WESTENBERG HG. Pharmacology of antidepressants: selectivity or multiplicity?
J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8.
WESTERMEYER J. Fluoxetine–induced tricyclic toxicity: extent and duration.
J Clin Pharmacol 1991; 31:388-392
WHARTON R, PEREL J, DAYTON P, MALITZ S. A potential clinical use for
methylphenidate with tricyclic antidepressants.
Am J Psychiatry 1971; 127:1619-1625
WHITE K, PISTOLE T, BOYD J L. Combiner monoamine oxidase inhibitor-tricyclic
antidepressant treatment: a pilot study.
Am J Psychiatry 1980; 137:1422-5.
WHITE CN, MISCOULON D, HERMAN JB, FREEDMAN SJ, ROSENBAUM JF, FAVA M, et al. How
often do the psychiatrics raise the dose when SSRIs do not work? 152nd Annual
meeting of the American Psychiatric Association. Washington, 1999. NR 128:97
WOLKOWITZ OM. Prospective controlled studies of the behavioral and biological
effects of exogenous corticosteroids. Psychoneuroendocrinol 1992; 19:233-255
WOLKOWITZ OM, REUS VI, MANFREDI F, CHAN T, ORMISTON S, JOHNSON R.
Dexamethasone for depression.
Am J Psychiatry 1996; 153:1112
WOLKOWITZ OM, REUS VI, CHAN T, et al. Antiglucocorticoid treatment
of depression: a double-blind ketoconazole study.
Biol Psychiatry 1999; 45:1070-1074
WOLKOWITZ OM, REUS VI, KEEBLER A, et al. Double-blind treatment of major
depression with dehydroepiandrosterone.
Am J Psychiatry 1999; 156:646-649
YASMIN S, CARPENTER LL, LEON Z, SINISCALCHI JM, PRICE LH. Adjunctive
gabapentine in treatment-resistant depression: a retrospective chart
review. Affect Disord 2001; 63:243-247
YOUNG JPR, LADER MH, HUGHES WC. Controled and trial of trimipramine, monoamine
oxidase inhibitors and combined tratment in depressed outpatients.
Br Med J 1979; 2:1315-7.
ZAJECKA JM, JEFFRIES H, FAWCETT J. The efficacy of fluoxetine combined
with a heterocylic antidepressant in treatment-resistant depression:
a retrospective analysis. J Clin Psychiatry 1995; 56:338-343
ZANARDI R, ARTIGAS F, FRANCHINI L, et al. How long should pindolol be
associated with paroxetine to improve the antidepressant response?
J Clin Psychopharmacol 1997; 17:446-450
ZEDKOVA L, COUPLAND NJ. Hypertensión during coprescription of mirtazapine and
low-dose amitryptiline. Can J Bakish D, Hooper CL, West DL et al. Moclobemide
ans specific serotonin reuptake inhibitor combination treatment of resistant anxiety
and depressive disorders. Human Psychopharmacol 1995; 10:105-109.
ZEDKOVA L, COUPLAND NJ. Hypertension during coprescription of mirtazapine and low
dose amitriptyline. Can J Psychiatry 1998; 43:858-859
ZHANG W, PERRY KW, WONG DT, et al. Synergistic effects of olanzapine and other
antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine
release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23:250-263
ZOHAR J, KAPLAN Z, AMSTERDAM JD. Reserpine augmentation in resistant
depression:a review. In: AMSTERDAM J, ed. Refractory Depression.
Raven Press, New York, 1991
|
|
|
|
|
|
